Skip to main content

Table 2 Multivariable analysis of CDX2 (absence versus any positive expression) adjusting for TNM stage and postoperative therapy

From: CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway

 

HR (95%CI)

p value

CDX2

 Negative

1.0

 

 Positive

0.35 (0.17–0.71)

0.0037

TNM stage

 TNM I (vs IV)

8.85 (4.05–19.2)

< 0.0001

 TNM II (vs IV)

6.33 (3.65–10.9)

< 0.0001

 TNM III (vs IV)

3.62 (2.18–6.02)

< 0.0001

Postoperative therapy

 None

1.0

 

 Treated

1.01 (0.83–1.23)

0.9172

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us